| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Ceftolozane/tazobactam |
| Brand | Zerbaxa® |
| Indication | For the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults. |
| Assessment Process | |
| Rapid review commissioned | 03/03/2016 |
| Rapid review completed | 26/04/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation recommended at the Submitted Price. |
September 2016
The HSE has approved reimbursement following confidential price negotiations.